SCHEDULE: Kiora Pharmaceuticals: Rosalind Discloses 9.9% Potential Stake

Rosalind Advisors and related entities disclose potential beneficial ownership of 9.9% of Kiora Pharmaceuticals common shares via warrants, currently unexercisable due to a blocker provision.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Kiora Pharmaceuticals Inc.
• The filing indicates a potential beneficial ownership of 464,676 common shares, representing 9.9% of the class.
• This percentage is calculated based on 3,433,491 common shares outstanding as of August 6, 2025, as reported by Kiora Pharmaceuticals in its 10Q filing.
• The 464,676 shares are issuable upon the exercise of pre-funded warrants.
• A blocker provision in these warrants prevents the holders from exercising them if it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Consequently, as of the event date (June 30, 2025), the reporting persons were unable to exercise any of these warrants due to the blocker.
• Despite holding the warrants, the reporting persons currently have no sole or shared voting or dispositive power over these shares.

Sentiment

Score: 6

Explanation: The filing indicates a significant potential stake by an institutional investor, Rosalind Master Fund L.P., in Kiora Pharmaceuticals, which can be viewed as a vote of confidence. However, the immediate impact is limited by a blocker provision preventing the exercise of warrants and thus current voting/dispositive power.

Positives

• A significant institutional investor (Rosalind Master Fund L.P. advised by Rosalind Advisors, Inc.) has acquired a substantial potential stake in Kiora Pharmaceuticals, indicating a long-term interest.
• The acquisition of pre-funded warrants suggests a strategic investment approach, potentially providing future capital to the company upon exercise, if blockers are removed or ownership thresholds change.

Negatives

• The blocker provision currently prevents the exercise of the warrants, meaning the reporting persons do not currently hold the underlying common shares or have voting/dispositive power over them.
• The inability to exercise warrants due to the blocker limits the immediate impact of this investment on the company's capital structure or governance.

Risks

• The pre-funded warrants held by Rosalind entities contain a blocker provision that prevents their exercise if it would result in beneficial ownership exceeding 9.99% of Kiora Pharmaceuticals' Common Stock, meaning the 464,676 shares are not currently exercisable.
• Due to the blocker, the reporting persons currently have no voting or dispositive power over the 464,676 shares, limiting their ability to influence corporate decisions or dispose of the shares.
• The exercise of these warrants and the conversion into common shares are contingent on the blocker provision no longer being active or the ownership threshold being adjusted, creating uncertainty regarding when or if these shares will become fully owned and exercisable.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant potential stake by an institutional investor could be viewed positively, potentially increasing investor confidence. However, the blocker provision means these shares do not currently carry voting rights, limiting immediate governance impact.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant potential beneficial ownership by Rosalind entities in Kiora Pharmaceuticals via pre-funded warrants. While the acquisition of a substantial stake by an institutional investor can be a positive signal, the critical detail is the blocker provision, which currently prevents the exercise of these warrants and thus eliminates any immediate voting or dispositive power. This limits the direct impact on the company's governance or capital structure from this specific filing. Without additional financial or operational updates, the filing itself does not provide sufficient grounds for a definitive buy or sell recommendation, suggesting a "hold" stance to observe future developments regarding the warrants and the company's performance.

Keywords

Kiora Pharmaceuticals, Rosalind Advisors, Rosalind Master Fund, Schedule 13G, beneficial ownership, common shares, warrants, pre-funded warrants, blocker provision, institutional investment, SEC filing